[go: up one dir, main page]

AR117994A1 - Métodos para tratar cáncer de mama triple negativo utilizando una proteína mutante de erbb-2 humana - Google Patents

Métodos para tratar cáncer de mama triple negativo utilizando una proteína mutante de erbb-2 humana

Info

Publication number
AR117994A1
AR117994A1 ARP200100292A ARP200100292A AR117994A1 AR 117994 A1 AR117994 A1 AR 117994A1 AR P200100292 A ARP200100292 A AR P200100292A AR P200100292 A ARP200100292 A AR P200100292A AR 117994 A1 AR117994 A1 AR 117994A1
Authority
AR
Argentina
Prior art keywords
erbb
mutant
breast cancer
negative breast
triple negative
Prior art date
Application number
ARP200100292A
Other languages
English (en)
Inventor
Mara Florencia Chervo
Patricia Virginia Elizalde
Original Assignee
Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet filed Critical Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet
Publication of AR117994A1 publication Critical patent/AR117994A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un método para tratar el cáncer de mama triple negativo en un sujeto, que comprende administrar una secuencia de ácidos nucleicos que codifica un polipéptido de ErbB-2 mutante en una cantidad efectiva para inhibir la proliferación de células cancerosas, en donde el ErbB-2 mutante carece de una señal de localización nuclear funcional, no puede translocarse al núcleo de la célula en la que está presente y funciona como un inhibidor dominante negativo de ErbB-2 endógeno al inhibir la translocación nuclear de ErbB-2 endógeno en la célula en la que está presente el mutante, en donde el polipéptido de ErbB-2 mutante retiene la actividad intrínseca de la tirosina quinasa y no inhibe la actividad de la tirosina quinasa de ErbB-2 endógeno.
ARP200100292A 2019-02-05 2020-02-04 Métodos para tratar cáncer de mama triple negativo utilizando una proteína mutante de erbb-2 humana AR117994A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962801282P 2019-02-05 2019-02-05

Publications (1)

Publication Number Publication Date
AR117994A1 true AR117994A1 (es) 2021-09-08

Family

ID=70005649

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100292A AR117994A1 (es) 2019-02-05 2020-02-04 Métodos para tratar cáncer de mama triple negativo utilizando una proteína mutante de erbb-2 humana

Country Status (2)

Country Link
AR (1) AR117994A1 (es)
WO (1) WO2020161614A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2544680B1 (en) * 2010-03-11 2015-01-14 Merrimack Pharmaceuticals, Inc. Use of erbb3 inhibitors in the treatment of triple negative breast cancer
US9427458B2 (en) * 2010-07-22 2016-08-30 Consejo Nacional De Investigaciones Cientificas Y Tecnicas, Conicet Methods for inhibiting cancer cell proliferation

Also Published As

Publication number Publication date
WO2020161614A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
Bian et al. Up-regulation of fatty acid synthase induced by EGFR/ERK activation promotes tumor growth in pancreatic cancer
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
EA202190474A1 (ru) Терапия на основе микро-рнк, направленная против lcp-1-позитивных раковых опухолей
Song et al. LncRNA SNHG8 promotes the development and chemo-resistance of pancreatic adenocarcinoma.
MY180365A (en) Markers of tumor cell response to anti-cancer therapy
BR112012022802A2 (pt) uso de um inibidor de erbb3, e, método de supressão de crescimento de uma célula e de um tumor de câncer de mama
SG10201908323TA (en) Method of treating malignant rhabdoid tumor of the ovary (mrto)/small cell cancer of the ovary of the hypercalcemic type (sccoht) with an ezh2 inhibitor
Cao et al. microRNA-33a-5p increases radiosensitivity by inhibiting glycolysis in melanoma
BR112015033053A2 (pt) método de tratamento de câncer em um sujeito, método de estimulação do sistema imune em um sujeito, método de aumentar a distribuição de um agente anticâncer a uma célula tumoral, composição, e kit
Zhang et al. Transport stress in broilers. II. Superoxide production, adenosine phosphate concentrations, and mRNA levels of avian uncoupling protein, avian adenine nucleotide translocator, and avian peroxisome proliferator-activated receptor-γ coactivator-1α in skeletal muscles
Zhang et al. ETS-1: A potential target of glycolysis for metabolic therapy by regulating glucose metabolism in pancreatic cancer
WO2023196978A3 (en) Myc program as a marker of response to enzalutamide in prostate
BR112022010072A2 (pt) Métodos que empregam óxido nítrico gasoso para inibir crescimento de tumor
WO2021162981A3 (en) Methods and compositions for identifying castration resistant neuroendocrine prostate cancer
MX2020013535A (es) Tratamiento de cáncer pulmonar de células no pequeñas (nsclc) en etapa iii y mitigación de las condiciones patológicas asociadas con el tratamiento.
AR101440A1 (es) MÚLTIPLES ARNi DIRIGIDOS PARA EL TRATAMIENTO DEL CÁNCER
CL2021002387A1 (es) Métodos para predecir el cáncer de próstata y usos de los mismos
Lagunas-Rangel Role of SIRT5 in cancer. Friend or Foe?
AR117994A1 (es) Métodos para tratar cáncer de mama triple negativo utilizando una proteína mutante de erbb-2 humana
Fan et al. microRNA-25 targets PKCζ and protects osteoblastic cells from dexamethasone via activating AMPK signaling
Mansouri et al. DICER governs characteristics of glioma stem cells and the resulting tumors in xenograft mouse models of glioblastoma
Endo et al. The FLCN-TFE3 axis regulates macrophage activation through cellular metabolism
WANG et al. Research on the expression of Survivin gene suppressed by pre-irradiation and intratumor injection siRNA in lung cancer of mouse
ZHANG et al. The effect of DRF1 silencing on the expression of MMP2 in glioma cell
DS et al. Lay Summary